My nephew is a regional sales manager for a medical device company and he has a hard time getting qualified salesman. When he does get one he treats him like gold cause he knows how valuable they can be.. It takes a certain personality to sell directly to doctors and I'm glad Chan is being picky...
The filter removes an array of pro and antiinflammatory cytokines...
There is a definite corrolation between elevated cytokines and negative outcomes..
The Renal research dept. at Fresenius(heavy hitters in the medical community) have formulated a theory of treatment called the "Peak Concentration Hypothesis" to treat severe sepsis patients..
This theory states the most logical approach to treating sepsis is removing as many of the pro and antiinflammatory cytokines thereby avoiding the all encompassing peak concentrations of cytokines which lead to septic storm and ultimately death...
I have confidence that this theory is correct and Cytosorbents will prevail in conquering this indication..
I also think the first step involves proving the filters efficacy in treating inflammation, the first step in sepsis.. Cardiac surgery is the convenient idiot in this journey..
Chan feels he can whip through a considerably less expensive trial treating these patients to prove the filters efficacy plain and simple..
I think if there were glowing results they would have rolled out the data by now..
I think we'll get more along the lines of the german trial where there is a lot of post hoc data that paints a picture of an opaque efficacy... This is the first data for this patient profile after all
I think the trial was seen as an overall success though as Chan has gone after this cardiac indication in the US after having known the results in Vienna for some time..
I've been here for 5 years and am out now but have been waiting for a dip like this to buy back in..
I think a cardiac trial success in the US will lead to on label uptake at decreasing inflammation in the ICU all around the world........